Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MRK
MERCK & CO., INC.
NYSE
$148.26
▼ DOWN 0.86% (-1.28)

KEY STATISTICS

Market Cap$366.18 B
52w High$156.92
52w Low$77.58
Dividend Yield2.61%
FrequencyQuarterly
P/E46.19
Volume7.69M
Shares Out.2.47B

COMPANY

LEADERSHIP

Robert Davis
CHIEF EXECUTIVE
Robert Davis

COMPENSATION 2026

Salary$1,645,302
Stock Awards$12,102,838
Incentive Plan Pay$2,326,500
All Other Comp.$658,058
Total$20,797,845

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 13, 1978
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
74,000

PRICE TARGET

Target High$180.00
Target Low$105.00
Target Median$150.00
Target Consensus$154.93

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$17.31B
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2021-06-03Forward131:125
1999-02-17Forward2:1
1992-05-26Forward3:1
1988-05-26Forward3:1
1986-05-27Forward2:1
1972-06-01Forward2:1
1964-05-27Forward3:1

PRICE

$148.26 ▼ DOWN 0.86% (−$1.28)
OVERLAYS
$148$148$1499:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM148.26

About Merck & Co., Inc.

https://www.merck.com ↗

Merck & Co. is a global healthcare company offering pharmaceuticals in oncology, immunology, vaccines, and neuroscience, along with veterinary health solutions, serving diverse healthcare providers and collaborating with major partners.

INDUSTRY

Drug Manufacturers - General

A PRODUCT MERCK & CO., INC. IS KNOWN FOR

Keytruda (pembrolizumab)
Keytruda (pembrolizumab)

Keytruda is a leading immunotherapy drug used to treat a wide variety of cancers. As a PD-1 inhibitor, it helps the body's own immune system to detect and fight cancer cells, making it a cornerstone of modern oncology and Merck's top-selling product.

COMPETITORS

COMPETITOR
AZN COMPARE
BMY COMPARE
JNJ COMPARE
LLY COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Pharmaceutical segment$15.61B $14.84B ▼$14.35B ▼$14.76B ▲
Animal Health segment$1.61B $1.5B ▼$1.79B ▲$1.77B ▼
Other Segments$50M $52M ▲$146M ▲$72M ▼

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$10.01B $9.14B ▼$9.16B ▲$9.37B ▲
EMEA$3.68B $3.79B ▲$3.89B ▲$3.92B ▲
Latin America$905M $854M ▼$874M ▲$875M ▲
Asia Pacific$764M $745M ▼$738M ▼$820M ▲
International$798M $784M ▼$679M ▼$640M ▼
JAPAN$712M $704M ▼$555M ▼$577M ▲
CHINA$405M $386M ▼$390M ▲$408M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,353
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.45% · 78.6M
SCHD
4.83% · 36.1M
IHVV.AX
0.57% · 33.0M
SPY
0.55% · 30.3M
VFLO
2.86% · 2.1M
DIVO
3.47% · 1.9M
DFAC
0.51% · 1.7M
JEPI
0.53% · 1.6M
LSPU.L
0.74% · 1.6M
RSP
0.23% · 1.6M
DGRW
1.36% · 1.5M
FTCS
2.25% · 1.2M
FHLC
5.06% · 1.2M
XDWH.L
4.30% · 1.2M
HMWO.L
0.83% · 1.0M
XZ
XZME.F
1.31% · 846.2K
VETS
7.40% · 778.4K
AVLV
0.54% · 776.1K
ZSP.TO
0.55% · 767.5K
PPH
10.99% · 753.6K
QLTY
2.10% · 629.3K
CGDG
1.44% · 547.3K
WRDUSW.SW
0.42% · 468.6K
SPYI
0.56% · 445.8K
GSLC
0.40% · 413.0K
PB
PBPH
5.42% · 376.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
52.24%
HOLDERS
5,023
TOP 12 OF 5,023 · RANKED BY POSITION SIZE
Vanguard Group Inc
254.3M sh · $26.77B
Blackrock, Inc.
227.0M sh · $29.17B
Blackrock Inc.
207.3M sh · $25.66B
State Street Corp
120.4M sh · $15.57B
Wellington Management Group Llp
86.4M sh · $9.1B
Blackrock Institutional Trust Company, N.A.
75.6M sh · $4.45B
Geode Capital Management, LLC
60.7M sh · $7.79B
Charles Schwab Investment Management Inc
54.4M sh · $6.99B
Sixth Street Partners Management Company, L.P.
54.4M sh · $6.99B
Jpmorgan Chase & Co
53.0M sh · $6.26B
Morgan Stanley
48.6M sh · $6.25B
Blackrock Fund Advisors
48.1M sh · $2.83B

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity3
Return On Assets4
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Josh Gottheimer
Josh Gottheimer
Purchase
2026-02-04
 Michael McCaul
Michael McCaul
Sale
2026-01-13
 Gilbert Cisneros
Gilbert Cisneros
Purchase
2025-12-19
 Julie Johnson
Julie Johnson
Sale
2025-12-18

INSIDER TRADES

★
OFFICER: EVP, ACCESS, POLICY & COMMS
Guindo Chirfi
Sale · 10.0K shares
2026-08-13
★
OFFICER: EVP, GENERAL COUNSEL
Zachary Jennifer
Purchase · 13.4K shares
2026-08-12
★
OFFICER: EVP, GENERAL COUNSEL
Zachary Jennifer
Purchase · 41.5K shares
2026-08-12
★
OFFICER: EVP, GENERAL COUNSEL
Zachary Jennifer
Sale · 80.3K shares
2026-08-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OVERWEIGHT 4
HOLD 4
OUTPERFORM 3
NEUTRAL 2
SECTOR PERFORM 1
SECTOR OUTPERFORM 1
20 GRADES IN THE LAST 12 MONTHS
Argus Research BUY Wolfe Research OUTPERFORM Goldman Sachs BUY BMO Capital OUTPERFORM UBS BUY RBC Capital SECTOR PERFORM Morgan Stanley OVERWEIGHT Daiwa Capital OUTPERFORM

SECTORS PEERS

PEERPRICE
NVS$153.81COMPARE
AZN$162.70COMPARE
AMGN$432.42COMPARE
TMO$622.18COMPARE
NVO$45.61COMPARE
ABT$112.47COMPARE
GILD$145.68COMPARE
PFE$27.96COMPARE